The rapid commercialization of GLP-1 weight-loss medications through non-medical channels is raising significant safety concerns among healthcare professionals in the UAE. What began as strictly controlled pharmaceutical treatments have now entered the consumer marketplace through subscription services, wellness clinics, and even home service apps.
Dr. Ali Hashemi, CEO of metabolic.health (GluCare), emphasizes that the medications themselves aren’t problematic when properly administered. ‘When prescribed appropriately with thorough screening and follow-up, they represent among the most significant advancements in metabolic health we’ve encountered,’ he stated. The danger emerges when these powerful drugs are treated as convenience products rather than serious medical interventions.
The acceleration of GLP-1 adoption, fueled by social media visibility and dramatic weight-loss results, has created a market ripe for exploitation. These medications are now being marketed through unconventional channels including aesthetic clinics, IV drip services, and online subscription platforms with minimal clinical oversight. Recently, consumer apps primarily known for home cleaning and spa services have begun promoting obesity treatments alongside their常规 services.
Medical professionals report seeing patients experiencing preventable complications from improperly managed GLP-1 regimens. These aren’t rare medical anomalies but practical management failures: excessively rapid dosage escalation, insufficient education on side-effect management, inadequate screening for contraindications, and absent follow-up care. Consequences include severe nausea, vomiting, dehydration, constipation, fatigue, and associated anxiety from feeling unwell and unsupported.
Beyond immediate side effects, experts highlight underreported risks such as significant muscle loss. Dr. Hashemi notes that without proper emphasis on protein intake, resistance training, and lean mass preservation, patients may achieve lower numbers on the scale while actually becoming weaker and less healthy.
Healthcare management specialist Dr. Sami Mohammed Yesuf warns that the primary risk resides not in the medications themselves but in delivery models that fragment care. ‘Obesity is a complex, chronic disease requiring comprehensive management,’ he explained. ‘When GLP-1 therapy is delivered outside proper medical frameworks, critical risks can be overlooked.’
The commercialization trend risks transforming obesity medicine from a clinical discipline into an add-on service, potentially leading to increased side effects, treatment discontinuation, weight rebound, and eroded public trust. Additional concerns include inconsistent medication sourcing when drugs are supplied outside regulated pharmacy channels.
Responsible GLP-1 programs, according to experts, must include proper medical screening, clear titration plans, proactive side-effect management, structured follow-up (especially within the first 8-12 weeks), muscle preservation strategies, and long-term maintenance planning. Patients are advised to inquire directly about prescription sources, side-effect management protocols, follow-up frequency, and medication origins before beginning treatment.
While innovation and improved access are welcomed, medical professionals stress that accountability remains non-negotiable. The current situation presents a critical juncture where clinical discipline must match commercial demand to prevent lasting damage to patient trust and outcomes.